China's Fermentation Giants Are Pivoting to Mycoprotein as Pharma Profits Thin

China's leading fermentation manufacturers are shifting production capacity from pharmaceuticals to mycoprotein and alternative proteins, driven by shrinking pharma margins and supported by state policies and new investments. This pivot could significantly alter the global economics of alternative protein production, presenting opportunities and risks for international companies considering partnerships in China.

This Wire brief sits within Fusion42's coverage of Foodtech.